Key facts
- It has raised $14.9M; the latest was Later Stage VC in Aug 2025.
- Notable investors include Taikun Fund, Bioinsight Ventures, Guanyou Development Investment, Hangzhou Tigermed Consulting Company, Lula Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for GCP Clinplus
- ·The full record, as it builds
Funding rounds
No funding rounds for GCP Clinplus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GCP Clinplus
Opeartor of a contract research organization catering to the clinical development of innovative pharmaceuticals and medical devices. The company's offerings feature full-service clinical research solutions for drugs, biopharmaceuticals, vaccines, cell and gene therapies, medical devices, traditional Chinese medicine, and natural medicines.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2010
- Employees
- 500
- Website
- gcp-clinplus.com/
- Ownership
- Privately Held (backing)
GCP Clinplus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GCP Clinplus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GCP Clinplus in its N-PORT filings yet. We sweep new filings monthly.